Genmab Reports 36% Revenue Growth in H1 2024
Genmab's H1 2024 results show 36% revenue growth; DARZALEX sales surge, and strategic acquisition of ProfoundBio boosts future potential.
- Latest
- Trending
Genmab's H1 2024 results show 36% revenue growth; DARZALEX sales surge, and strategic acquisition of ProfoundBio boosts future potential.
RYVYL Inc. reports 134% international revenue growth in Q2 2024, offsetting North American decline.
Stock markets gain globally as investors anticipate a Federal Reserve interest rate cut amid positive economic indicators.
Glanbia reports 12.4% EPS growth in H1 2024 amid strong demand and strategic acquisitions.
Brain implants and AI voice technology enable ALS patients to communicate effectively.
European countries import gold with unclear origins, raising legal and ethical concerns over Amazon mining practices.
Mastercard and MetaMask unveil a crypto card to simplify spending digital assets in fiat currency globally.
Discover how UNECE WP.29 regulations and AWS IoT enhance vehicle cybersecurity with comprehensive and scalable solutions.
Zebra Technologies leads supply chain efficiency with innovative tech, gaining investor interest in 2024.
Exploring the impact of AI bias in healthcare and solutions to ensure equitable patient care.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.